Market cap
$23 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -56.64 | -14.63 | 541.54 |
| EBIT | -- | -- | 87.82 | 23.49 | 14.22 |
| Net Profit | 42.56 | 54.52 | 40.39 | 10.29 | 11.91 |
| EPS | 42.56 | 67.14 | 64.22 | 19.07 | 13.95 |
| Book Value | -- | -- | -46.20 | -22.24 | -27.88 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -293.07 | -1,130.42 | -85.55 | -- | -162.06 |
| Net Margin
| -- | -- | -372.69 | -- | -- |
| Return on equity
| -61.19 | -79.03 | -60.13 | -68.81 | -65.81 |
| Return on Capital
| -58.18 | -66.87 | -- | -68.81 | -65.81 |
| Return on Assets
| -48.66 | -55.60 | -36.12 | -59.20 | -54.82 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
-68.81
|
-65.81
|
-39.92
|
-72.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-60.13
Lower than Peers by 19.73
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-60.13
|
-68.81
|
-65.81
|
-48.95
|
-94.14
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-36.12
Lower than Peers by 5.14
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-36.12
|
-59.20
|
-54.82
|
-31.96
|
-58.37
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-85.55
Lower than Peers by 1.93
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-85.55
|
--
|
-162.06
|
-424.09
|
-562.85
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-372.69
Lower than Peers by 280.02
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-372.69
|
-342.96
|
-162.82
|
-248.76
|
-851.87
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
-56.64
Lower than Peers by 110.59
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-56.64
|
-0.46
|
0.99
|
-0.06
|
1.83
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
87.82
Higher than Peers by 88.62
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
87.82
|
--
|
23.93
|
28.99
|
52.78
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
40.39
Higher than Peers by 47.69
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
40.39
|
-13.35
|
-30.28
|
72.48
|
28.53
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
64.22
Higher than Peers by 49.57
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
64.22
|
0.33
|
-0.27
|
0.74
|
0.29
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-16.20
Lower than Peers by 6.03
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-16.20
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
--
|
--
|
0.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
--
|
--
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.03
Higher than Peers by 0.22
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
6.03
|
8.39
|
6.36
|
5.57
|
2.14
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
6.03
Higher than Peers by 0.33
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
6.03
|
--
|
--
|
5.89
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
--
|
--
|
-1,310.62
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
69.32
Higher than Peers by 50.18
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
69.32
|
38.60
|
35.60
|
31.04
|
68.36
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.10
Higher than Peers by 0.03
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
0.10
|
0.17
|
0.34
|
0.13
|
0.07
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
191.33
|
93.50
|
189.17
|
124.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
-26.80
|
-34.65
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
27.49
|
36.15
|
95.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
39.22
|
118.37
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
-1.88
|
-2.64
|
-5.94
|
-0.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.00
Lower than Peers by 3.18
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
2.00
|
1.36
|
1.53
|
3.48
|
0.11
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.22
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
-0.22
|
-0.54
|
1,796,813.49
|
-3.01
|
0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
23
Lower than Peers by 123
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
23
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|